Royalty Pharma (RPRX) Non Operating Income (2019 - 2026)

Royalty Pharma has disclosed Non Operating Income across 8 years of filings, most recently posting -$94.8 million for Q1 2026.

• Non Operating Income for Q1 2026 came in at -$94.8 million, up 4.98% year-over-year; the trailing twelve-month figure through Mar 2026 was $90.6 million (up 137.18% YoY), and the FY2025 annual result was -$14.3 million, down 839.07% from the prior year.
• Non Operating Income came in at -$94.8 million for Q1 2026 at Royalty Pharma, down from $188.5 million in the prior quarter.
• In the past five years, Non Operating Income ranged from a high of $211.4 million in Q4 2023 to a low of -$99.7 million in Q1 2025.
• The 5-year median for Non Operating Income is -$1.6 million (2025), against an average of $13.5 million.
• Across the five-year window, Non Operating Income jumped 18243.09% in 2023 and tumbled 6997.62% in 2024, its largest moves.
• Royalty Pharma's Non Operating Income stood at -$1.2 million in 2022, then surged by 18243.09% to $211.4 million in 2023, then sank by 131.73% to -$67.1 million in 2024, then soared by 381.1% to $188.5 million in 2025, then sank by 150.28% to -$94.8 million in 2026.
• The last three Non Operating Income figures came in at -$94.8 million (Q1 2026), $188.5 million (Q4 2025), and -$1.6 million (Q3 2025), per Business Quant data.